{
  "compound": "Nabiximols (Sativex)",
  "condition": "CANCER_PALLIATIVE",
  "effect_size": "Medium (d = 0.55)",
  "study_type": "RCT",
  "source": "NORML:CANCER_RCT_001",
  "participants": "360 patients with advanced cancer pain",
  "year": 2012,
  "notes": "Nabiximols for Cancer Pain Uncontrolled by Opioids: Phase III Trial",
  "confidence": "medium",
  "abstract": "Low-dose nabiximols: 30% improvement rate vs Placebo: 22%; Per-protocol: 43% vs 21% (p<0.05); Significant in compliant patients"
}